BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Ferreira VL, Leonart LP, Pedroso MLA, Pontarolo R. Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil. Rev Soc Bras Med Trop 2020;53:e20190594. [PMID: 32578707 DOI: 10.1590/0037-8682-0594-2019] [Reference Citation Analysis]
2 Fu Z, Dong C, Ge Z, Wang C, Zhang Y, Shen C, Li J, Zhu C, Wang Y, Huang P, Yue M. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis. Front Med (Lausanne) 2021;8:608760. [PMID: 34169081 DOI: 10.3389/fmed.2021.608760] [Reference Citation Analysis]
3 Yang CHT, Goel A, Ahmed A. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolesc Health Med Ther 2018;9:103-10. [PMID: 30104913 DOI: 10.2147/AHMT.S147896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
5 Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. JAMA Netw Open 2020;3:e2015756. [PMID: 32880650 DOI: 10.1001/jamanetworkopen.2020.15756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
6 Abutaleb A, Sherman KE. A changing paradigm: management and treatment of the HCV/HIV-co-infected patient. Hepatol Int 2018;12:500-9. [PMID: 30238230 DOI: 10.1007/s12072-018-9896-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
7 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Caroleo B, Caroleo MC, Cimellaro A, Colangelo L, Perticone M, Di Mizio G, De Sarro G, Gallelli L. Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation. Curr Drug Saf 2019;14:67-71. [PMID: 30444202 DOI: 10.2174/1574886313666181116100452] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Aghemo A, Alberti A, Andreone P, Angelico M, Brunetto MR, Chessa L, Ciancio A, Craxì A, Gaeta GB, Galli M, Gasbarrini A, Giorgini A, Grilli E, Lampertico P, Lichtner M, Milella M, Morisco F, Persico M, Pirisi M, Puoti M, Raimondo G, Romano A, Russello M, Sangiovanni V, Schiavini M, Serviddio G, Villa E, Vinci M, De Michina A, Gallinaro V, Gualberti G, Roscini AS, Zignego AL; MARS Study Group. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Dig Liver Dis 2021;53:612-9. [PMID: 32917546 DOI: 10.1016/j.dld.2020.08.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wettersten N, Tran H, Mekeel K, Pretorius V, Adler E, Aslam S. Successful heart-kidney transplantation from a Hepatitis C viremic donor to negative recipient: One year of follow-up. Transpl Infect Dis 2019;21:e13002. [PMID: 30222242 DOI: 10.1111/tid.13002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Huff J, Andersen R. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Ann Pharmacother 2020;54:262-76. [PMID: 31537106 DOI: 10.1177/1060028019877128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Wu W, Lin J, Xiao J, Cao Y, Ma Y. Recent Advances in the Synthesis of CF 3 ‐ or HCF 2 ‐Substituted Cyclopropanes. Asian J of Organic Chemis 2021;10:485-95. [DOI: 10.1002/ajoc.202000723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Moayedi Y, Gulamhusein AF, Khush KK. Treading lightly as we step into a new era: Use of hepatitis C virus-infected organs for transplantation. J Thorac Cardiovasc Surg 2020;159:505-10. [PMID: 31587888 DOI: 10.1016/j.jtcvs.2019.05.091] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]